These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35434139)

  • 21. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
    Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
    JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study.
    Palanca A; Ampudia-Blasco FJ; Calderón JM; Sauri I; Martinez-Hervás S; Trillo JL; Redón J; Real JT
    Diabetes Res Clin Pract; 2024 Jan; 207():111071. PubMed ID: 38142748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
    Lajara R
    Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2021 Nov; 20(1):222. PubMed ID: 34774054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Consensus recommendations on utilizing glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus].
    ;
    Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):836-846. PubMed ID: 33120487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
    Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
    Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists.
    Wu Q; Li D; Huang C; Zhang G; Wang Z; Liu J; Yu H; Song B; Zhang N; Li B; Chu X
    Biomed Pharmacother; 2022 Sep; 153():113517. PubMed ID: 36076602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
    Liu Y; Tian Q; Yang J; Wang H; Hong T
    Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.
    Zhao X; Wang M; Wen Z; Lu Z; Cui L; Fu C; Xue H; Liu Y; Zhang Y
    Front Endocrinol (Lausanne); 2021; 12():721135. PubMed ID: 34497589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
    Htoo PT; Buse J; Cavender M; Wang T; Pate V; Edwards J; Stürmer T
    J Am Heart Assoc; 2022 Feb; 11(4):e022376. PubMed ID: 35132865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.
    Widiarti W; Sukmajaya AC; Nugraha D; Alkaff FF
    Diabetes Metab Syndr; 2021; 15(3):837-843. PubMed ID: 33866119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
    Owens DR; Monnier L; Hanefeld M
    Diabetes Obes Metab; 2017 Dec; 19(12):1645-1654. PubMed ID: 28474401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.